A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

@article{Giantonio2006API,
  title={A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.},
  author={Bruce J. Giantonio and Donna E. Levy and Peter J. O'dwyer and Neal J. Meropol and Paul J. Catalano and Al Bowen Benson},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2006},
  volume={17 9},
  pages={1399-403}
}
AIM Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL. The first 20 patients received irinotecan (125 mg/m(2)), 5-fluorouracil (500 mg/m(2)) and leucovorin (20 mg/m(2)) weekly for four of six weeks and high-dose bevacizumab (10 mg/kg) every other week. Following a toxicity review of other trials using IFL, subsequent patients were enrolled at reduced doses of irinotecan (100 mg/m(2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Novel fluorinated docetaxel analog for anti-hepatoma: Molecular docking and biological evaluation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…